This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Freeman, M. R. Articles by Armstrong, P. W. Search for Related Content PubMed PubMed Citation Articles by Freeman, M. R. Articles by Armstrong, P. W.

Circulation, Vol 85, 150-157, Copyright © 1992 by American Heart Association

ARTICLES

Thrombolysis in unstable angina. Randomized double-blind trial of t-PA and placebo

MR Freeman, A Langer, RF Wilson, CD Morgan and PW Armstrong
Department of Medicine, St. Michael's Hospital, University of Toronto, Ontario, Canada.

BACKGROUND. Because coronary thrombosis is important in the pathogenesis of unstable angina and correlates with in-hospital cardiac events, we hypothesized that thrombolytic therapy would decrease cardiac events. METHODS AND RESULTS. We randomized 70 patients with unstable angina to tissue-type plasminogen activator (t-PA) (0.49 MU/kg for 1 hour followed by 0.07 MU/kg per hour for 9 hours) or placebo. All patients received full doses of intravenous heparin for 96 hours and aspirin (325 mg beginning at 72 hours). The primary end points of the study were in-hospital death, myocardial infarction, and urgent revascularization. Three secondary end points were also evaluated. Myocardial perfusion was assessed with resting planar thallium scintigraphy 90 minutes after initiation of therapy. Silent ischemia was assessed with 48-hour Holter monitoring for ST shift beginning at time of initiation of drug therapy. Coronary angiography was performed at 18 +/- 6 hours and analyzed quantitatively to assess the stenosis responsible for unstable angina, the presence of intraluminal filling defects consistent with intracoronary thrombus, and stenosis morphology and severity. There was no difference in total in-hospital cardiac events between patients receiving t-PA (5% or 14%) and those receiving placebo (7% or 20%) (p = 0.83). Resting thallium defects were larger in the patients receiving t-PA than in those receiving placebo (130 +/- 118 versus 76 +/- 84 degrees, p less than 0.04), and this difference persisted when corrected for previous infarction. Although the numbers of patients with ST shift were similar, the duration of ST shift was significantly longer in the patients receiving t-PA than with placebo (20 +/- 46 versus 3 +/- 10 minutes, p less than 0.045). The frequency of intracoronary thrombi in patients with stenoses greater than 50% was significantly less in patients treated with t-PA (11 of 22, 52%) as compared with placebo (23 of 25, 92%) (p = 0.002), but there was no significant difference in minimal lesion cross-sectional area (0.49 +/- 0.42 versus 0.57 +/- 1.08 cm2, p = 0.75) or ulceration index (0.79 +/- 0.16 versus 0.77 +/- 0.15, p = 0.71) of the culprit artery. CONCLUSIONS. We conclude that a prolonged infusion of t-PA in unstable angina reduces intracoronary thrombi but does not significantly decrease in-hospital cardiac events. The sample size, however, does not provide sufficient power to rule out a treatment effect. Paradoxically, there appears to be an increase in ST shift and worsening of myocardial perfusion with t-PA compared with therapy with heparin alone.

This article has been cited by other articles:

				T. N. Martin, B. A. Groenning, H. M. Murray, T. Steedman, J. E. Foster, A. T. Elliot, H. J. Dargie, R. H. Selvester, O. Pahlm, and G. S. Wagner ST-Segment Deviation Analysis of the Admission 12-Lead Electrocardiogram as an Aid to Early Diagnosis of Acute Myocardial Infarction With a Cardiac Magnetic Resonance Imaging Gold Standard J. Am. Coll. Cardiol., September 11, 2007; 50(11): 1021 - 1028. [Abstract] [Full Text] [PDF]

				G. N. Levine, M. N. Ali, and A. I. Schafer Antithrombotic Therapy in Patients With Acute Coronary Syndromes Arch Intern Med, April 9, 2001; 161(7): 937 - 948. [Abstract] [Full Text] [PDF]

				X.-Q. Zhao, P. Theroux, S. M. Snapinn, and F. L. Sax Intracoronary Thrombus and Platelet Glycoprotein IIb/IIIa Receptor Blockade With Tirofiban in Unstable Angina or Non-Q-Wave Myocardial Infarction : Angiographic Results From the PRISM-PLUS Trial (Platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms) Circulation, October 12, 1999; 100(15): 1609 - 1615. [Abstract] [Full Text] [PDF]

				R. P. Giugliano, C. A. Camargo Jr, D. M. Lloyd-Jones, J. D. Zagrodsky, J. D. Alexis, K. A. Eagle, V. Fuster, and C. J. O'Donnell Elderly Patients Receive Less Aggressive Medical and Invasive Management of Unstable Angina: Potential Impact of Practice Guidelines Arch Intern Med, May 25, 1998; 158(10): 1113 - 1120. [Abstract] [Full Text] [PDF]

				S. Richard, F. Leclercq, S. Lemaire, C. Piot, and J. Nargeot Ca2+ currents in compensated hypertrophy and heart failure Cardiovasc Res, February 1, 1998; 37(2): 300 - 311. [Abstract] [Full Text] [PDF]

				M. Owa, H. Origasa, M. Saito, and M. Owa Predictive Validity of the Braunwald Classification of Unstable Angina for Angiographic Findings, Short-Term Prognoses, and Treatment Selection Angiology, August 1, 1997; 48(8): 663 - 671. [Abstract] [PDF]

				H. V. Anderson and J. T. Willerson Thrombolysis in Acute Myocardial Infarction N. Engl. J. Med., September 2, 1993; 329(10): 703 - 709. [Full Text]